EMERALD-3- STRIDE-Based Therapy Improves PFS in TACE-Eligible HCC: The Lancet | September 2026

Introduction:

TACE remains a standard treatment for embolisation-eligible HCC, but recurrence and progression are common. Because TACE can enhance tumor antigen release and immune activation, combining it with systemic immunotherapy—and potentially antiangiogenic therapy—may improve disease control. EMERALD-3 tested STRIDE (tremelimumab + durvalumab), with or without lenvatinib, plus TACE versus TACE alone.

Why was this study needed?

TACE alone often provides incomplete and temporary tumor control.

STRIDE is already established in advanced HCC.

Lenvatinib may enhance antiangiogenic control and complement immunotherapy.

The key question was whether systemic therapy could improve outcomes earlier in embolisation-eligible disease.

Results:

760 patients were randomized to STRIDE + lenvatinib + TACE, STRIDE + TACE, or TACE alone.

STRIDE + lenvatinib + TACE significantly improved PFS: 13.0 vs 9.8 months with TACE alone (HR 0.70).

STRIDE + TACE also improved PFS versus TACE: 12.9 vs 8.1 months (HR 0.71).

Median OS with the triplet was 39.5 vs 34.7 months, but this difference was not yet statistically significant (HR 0.84; P=0.18).

Toxicity increased with systemic therapy, particularly with the triplet; serious adverse events occurred in 64%, and treatment-related deaths occurred in 2%.

Clinical Impact:

EMERALD-3 strengthens the emerging concept that intermediate-stage or TACE-eligible HCC should not necessarily be managed with locoregional therapy alone.

A new paradigm is taking shape:

TACE + immunotherapy ± antiangiogenic therapy → deeper and more durable disease control

However, the triplet comes with substantial toxicity, and the final overall-survival analysis remains critical before defining its precise place in routine practice.

Bottom Line:

Adding STRIDE-based systemic therapy to TACE significantly prolonged progression-free survival in embolisation-eligible HCC. The STRIDE + lenvatinib + TACE triplet reduced progression risk by about 30%, but overall-survival benefit is not yet proven and toxicity is higher. EMERALD-3 supports the ongoing shift from TACE-alone toward integrated locoregional–systemic therapy in intermediate-stage HCC.